DexCom announces Q3 2026 results and $1B share repurchase

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On October 29, 2026, DexCom, Inc. ("Dexcom") issued a press release announcing its financial results for the quarter ended September 30, 2026¹ and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report.²

The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934², as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

ITEM 8.01.

OTHER EVENTS.

On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock³, par value $0.001 per share ("Common Stock"), with a repurchase period ending no later than December 31, 2027³ (the "Share Repurchase Program").

Repurchases of Common Stock under the Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act , at Dexcom's discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at Dexcom's discretion.

The Share Repurchase Program does not obligate Dexcom to repurchase any dollar amount or number of shares of Common Stock, and the program may be extended, modified, suspended, or discontinued at any time.⁴

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Number Description

99.1 Press release dated October 29, 2026

104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DEXCOM, INC.

By: /s/ JEREME SYLVAIN

Jereme Sylvain

Executive Vice President, Chief Operating Officer and Chief Financial Officer

(Principal Financial and Accounting Officer)

Date:

October 29, 2026

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO - (BUSINESS WIRE-October 29, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights:

• Revenue grew 11% year-over-year to $1.344 billion on a reported basis and 11% year-over-year on an organic 1 basis.

• U.S. revenue grew 14% and international revenue grew 5% on a reported basis and 5% on an organic 1 basis⁶, all on a year-over-year basis.

• GAAP operating income of $327.2 million or 24.3% of revenue, an increase of 420 basis points compared to the third quarter of 2025. Non-GAAP operating income* of $339.5 million or 25.3% of reported revenue, an increase of 270 basis points compared to the third quarter of 2025.

Third Quarter 2026 Strategic Highlights:

• Subsequent to the quarter, published the CONNECT randomized clinical trial in The New England Journal of Medicine , showcasing outcomes driven by Dexcom G7 that redefine the standard of care for people with Type 2 diabetes not on insulin.

• Launched the fully redesigned Stelo experience, with enhanced glucose insights, simplified meal logging, and more detailed nutritional information.

• Advanced the rollout of the Dexcom G7 15 Day System in the U.S. and secured first two G7 15 Day international regulatory clearances, positioning for continued momentum in the transition of the global base to the extended wear platform.

"This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives," said Jake Leach, Dexcom's president and CEO. "This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day."

2026 Annual Guidance

• Non-GAAP Gross Profit Margin of approximately 64%

• Non-GAAP Operating Margin of approximately 24%

• Adjusted EBITDA Margin of approximately 32%

The company also announced a share repurchase authorization of up to $1.0 billion in conjunction with third quarter results.

Third Quarter 2026 Financial Results

Revenue: In the third quarter of 2026, worldwide revenue grew 11% to $1.344 billion on a reported basis, up from $1.209 billion in the third quarter of 2025.⁵

Gross Profit: GAAP gross profit totaled $864.4 million or 64.3% of revenue for the third quarter of 2026, compared to $731.4 million or 60.5% of revenue in the third quarter of 2025.

1 Third quarter 2026 organic revenue was $1.346 billion and excludes $1.7 million of foreign exchange impact and $0.7 million of acquired non-CGM revenue.

Non-GAAP gross profit* totaled $875.3 million or 65.1% of reported revenue for the third quarter of 2026, compared to $741.3 million or 61.3% of reported revenue in the third quarter of 2025.

Operating Income: GAAP operating income for the third quarter of 2026 was $327.2 million or 24.3% of revenue, compared to GAAP operating income of $242.5 million or 20.1% of revenue for the third quarter of 2025.⁷

Non-GAAP operating income* for the third quarter of 2026 was $339.5 million or 25.3% of reported revenue, compared to non-GAAP operating income of $272.9 million or 22.6% of reported revenue for the third quarter of 2025.

Net Income and Diluted Net Income Per Share: GAAP net income was $275.1 million, or $0.72 per diluted share, for the third quarter of 2026, compared to GAAP net income of $283.8 million, or $0.70 per diluted share, for the third quarter of 2025.⁸

Non-GAAP net income* was $275.0 million, or $0.73 per diluted share, for the third quarter of 2026, compared to non-GAAP net income of $242.5 million, or $0.61 per diluted share, for the third quarter of 2025. The third quarter 2026 non-GAAP net income excludes $11.9 million of amortization of intangible assets, $0.4 million of business transition and other significant items, and $12.4 million of tax adjustments.

Cash and Liquidity: As of September 30, 2026, Dexcom held $1.82 billion in cash, cash equivalents and marketable securities⁹ and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

* See Table D below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to "Events and Presentations," and will be archived for future reference. To listen to the conference call, please dial (888) 414-4585 (U.S./Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.

Statement Regard